An unexpected outcome to a troubling behavior problem/Job appraisal: Pediatricians are a contented lot
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
FDA grants fast track to rezpegaldesleukin for severe alopecia areata in ages 12 and up
Nektar Therapeutics remains on track to announce topline phase 2 data in December.
Food Insecurity and the Dangers of Infant Formula Dilution
FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN
Pegcetacoplan (Empaveli: Apellis PHarmaceuticals) is indicated for patients aged 12 years and older to reduce proteinuria.
Demystifying Infant Formula
FDA approves sepiapterin to treat phenylketonuria in adult, pediatric patients
“Without treatment, individuals with PKU would have very high blood Phe levels... so that results in neurocognitive deficits and mood disorders," Suzanne Hollander, MS, RD, LDN.
FDA approves avatrombopag for pediatric immune thrombocytopenia, including new sprinkle formulation
The FDA has approved avatrombopag and new sprinkle formulation for children ≥1 year with chronic ITP, offering an oral, food-flexible treatment option.